Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

Igarashi, Ataru; Hirose, Emi; Kobayashi, Yasuhiro; Yonemoto, Naohiro; Lee, Bennett

doi:10.1080/14760584.2021.1952869

Cited by 14 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the suggested willingness-to-pay (WTP) value per QALY gained in Japan is ¥5 million/QALY gained [ 25 ], an ICER range rather than a uniform price threshold has been proposed to be more appropriate in policy settings in Japan [ 26 ]. Hence, in the current study, an ICER below the range of ¥5–6 million/QALY gained was considered as cost-effective in Japan, consistent with the generally accepted cost-effectiveness threshold previously reported for the cost-effectiveness analysis of pneumococcal vaccination [ 27 ].…”

Section: Methodssupporting

confidence: 71%

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults

Teng

Mizukami

Ng³

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction This study aimed to update cost-effectiveness and public health impact estimates of the two-dose recombinant zoster vaccine (RZV) compared with no vaccination against herpes zoster (HZ) in the Japanese population aged 65 years. List price of the vaccine and latest RZV efficacy and waning estimates were incorporated. Methods A multicohort static Markov model with a cycle length of 1 year was used to follow a hypothetical cohort of one million people aged 65 years over their remaining lifetime (base case). Age-stratified vaccine efficacy and waning rates were updated on the basis of the latest clinical trial data (interim ZOE-LTFU; NCT02723773). First-dose coverage was assumed at 40%, and second-dose compliance was assumed at 95%. Costs and outcomes were discounted at 2% annually, and the incremental cost-effectiveness ratio (ICER) was calculated from payer and societal perspectives. The societal perspective considered productivity loss due to suffering HZ, or due to suffering HZ and time required for vaccination. Sensitivity analyses explored the overall uncertainties in the model. Scenario analyses for Japanese adults aged 50, 60, 70, 80, ≥ 50, and ≥ 65 years (main scenario) were conducted. An ICER below ¥5–6 million/quality-adjusted life-year (QALY) was considered cost-effective. Results RZV was estimated to prevent 71,423 HZ cases and 15,858 post-herpetic neuralgia (PHN) cases per million people aged 65 years compared with no vaccine in Japan. The ICER was ¥4,205,515 from a payer perspective and was most sensitive to assumptions regarding vaccine efficacy waning, proportion of patients with HZ developing PHN, and HZ incidence. From societal perspectives, ICERs were ¥3,854,192 (productivity loss from suffering HZ only) and ¥4,622,212 (productivity loss from suffering HZ and time required for vaccination). Overall, the results were considered robust under extensive sensitivity and scenario analyses. Conclusion Vaccination against HZ with RZV is cost-effective compared with no vaccination in Japanese adults aged 65 years. Graphical abstract Supplementary Information The online version contains supplementary material available at 10.1007/s13555-022-00744-8.

show abstract

Section: Methodssupporting

confidence: 71%

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults

Teng

Mizukami

Ng³

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Estimates of mortality included in the current analysis represent in-hospital mortality only, and therefore any COVID-19 related deaths occurring post-discharge are not captured. For the societal cost perspective, we considered short-term lost productivity but did not have data on long-term losses or other informal health care resource used, such as caregiver time, 62 or other impact of family spillover. 63 The impact of COVID-19 using the societal cost perspective is therefore under-estimated.…”

Section: Discussionmentioning

confidence: 99%

The potential economic impact of the updated COVID-19 mRNA fall 2023 vaccines in Japan

Fust,

Joshi,

Beck

et al. 2023

Preprint

View full text Add to dashboard Cite

This analysis estimates the economic and clinical impact of a Moderna updated COVID-19 mRNA Fall 2023 vaccine for adults ≥18 years in Japan. A previously developed Susceptible-Exposed-Infected-Recovered (SEIR) model with a 1-year analytic time horizon (September 2023-August 2024) and consequences decision tree were used to estimate symptomatic infections, COVID-19–related hospitalizations, deaths, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratio (ICER) for a Moderna updated Fall 2023 vaccine versus no additional vaccination, and versus a Pfizer-BioNTech updated mRNA Fall 2023 vaccine. The Moderna vaccine is predicted to prevent 7.2 million symptomatic infections, 272,100 hospitalizations and 25,600 COVID-19 related deaths versus no vaccine. In the base case (healthcare perspective), the ICER was ¥1,300,000/QALY gained ($9,400 USD/QALY gained). Sensitivity analyses suggest results are most affected by COVID-19 incidence, initial vaccine effectiveness (VE), and VE waning against infection. Assuming the relative VE between both bivalent vaccines apply to updated Fall 2023 vaccines, the base case suggests the Moderna version will prevent an additional 1,100,000 symptomatic infections, 27,100 hospitalizations, and 2,600 deaths compared to the Pfizer-BioNTech vaccine. The updated Moderna vaccine is expected to be highly cost-effective at a ¥5 million willingness-to-pay threshold across a wide range of scenarios.

show abstract

“…Case fatality rate were derived using data from Asia-Pacific countries ( 24 ) and assumed with an odds ratio for immunocompromised conditions between 1.3 and 1.8. This similar approach was used in the previous published economic analysis ( 12 , 20 ). The proportion of IPD outcomes and incidence of pneumococcal disease complications were assumed to be equal for infected healthy individuals, those with chronic health conditions and those with immunocompromised conditions.…”

Section: Methodsmentioning

confidence: 99%

“…According to some economic studies, either PCV13 or the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is cost-effective among the older adult. Igarashi et al ( 12 ) performed a cost-effectiveness analysis of PCV13 and PPSV23 in older adult aged ≥ 60 years in a Japanese health care setting. The study showed that PCV13 was more cost-effective than PPSV23 ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

“…Igarashi et al ( 12 ) performed a cost-effectiveness analysis of PCV13 and PPSV23 in older adult aged ≥ 60 years in a Japanese health care setting. The study showed that PCV13 was more cost-effective than PPSV23 ( 12 ). Meanwhile, the study conducted in Denmark suggested that implementing a PPSV23 vaccination program for all older adult aged ≥ 65 years is cost-effective ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult

Ngamprasertchai

Kositamongkol

Lawpoolsri

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

IntroductionThis study aims to assess the economic impact of introducing the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) to Thai older adult aged ≥ 65 years who are healthy or with chronic health conditions and immunocompromised conditions from a societal perspective in order to introduce the vaccine to Thailand’s National Immunization Program for the older adult.MethodsA Markov model was adopted to simulate the natural history and economic outcomes of invasive pneumococcal diseases using updated published sources and Thai databases. We reported analyses as incremental cost-effectiveness ratios (ICER) in USD per quality-adjusted life year (QALY) gained. In addition, sensitivity analyses and budget impact analyses were conducted.ResultsThe base-case analysis of all interventions (no vaccinations [current standard of care in Thailand], PPSV23, and PCV13) showed that PPSV23 was extendedly dominated by PCV13. Among healthy individuals or those with chronic health conditions, ICER for PCV13 was 233.63 USD/QALY; meanwhile, among individuals with immunocompromised conditions, ICER for PCV13 was 627.24 USD/QALY. PCV13 are economical vaccine for all older adult Thai individuals when compared to all interventions.ConclusionsIn the context of Thailand, PCV13 is recommended as the best buy and should be primarily prioritized when both costs and benefits are considered. Also, this model will be beneficial to the two-next generation pneumococcal vaccines implementation in Thailand.

show abstract

Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

Cited by 14 publications

References 35 publications

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults

The potential economic impact of the updated COVID-19 mRNA fall 2023 vaccines in Japan

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult

Contact Info

Product

Resources

About